Fourth-Quarter Miss Sinks Wells Fargo Stock

Analysts are already quite bearish on the stock

by Lillian Currens

Published on Jan 14, 2020 at 9:19 AM

The shares of Wells Fargo & Co (NYSE:WFC) are struggling today. The bank concern stepped into the earnings confessional with adjusted fourth-quarter earnings of 93 cents per share, lower than the $1.12 estimates and down 55% year-over-year due to mounting legal costs and a lower interest rate environment. The firm also posted revenue of $19.9 billion that was below analysts' estimates. At last check, WFC is down 3.7% before the bell in response.

On the charts, the stock has been sinking lower after consolidating under the $54.50 region in November and December. Yesterday, WFC was testing its footing at the 80-day moving average -- a trendline the equity just finished south of for the first time in four months. The stock is still set to hang on to its year-over-year gain, though. 

While the brokerage bunch has been quiet this morning, there's already plenty of caution surrounding Wells Fargo. In fact, 17 in coverage call it a "hold" or worse, while only two see it as a "strong buy." What's more, the consensus 12-month target price of $53.33 is a slim 2.3% premium to last night's close of $52.11. 

There has been a preference for puts in the options pits. Currently, WFC sports a Schaeffer's put/call open interest ratio (SOIR) of 1.06, which sits in the 90th percentile of its annual range. This suggests that short-term option players have rarely been more put heavy in the last 12 months. 


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Protect Your Retirement Savings Now
Click to continue to advertiser's site.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.